- Home
- ABEO vs SOPH Comparison
ABEO vs SOPH Comparison
Compare ABEO & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- SOPH
- Stock Information
- Founded
- ABEO 1974
- SOPH 2011
- Country
- ABEO United States
- SOPH Switzerland
- Employees
- ABEO N/A
- SOPH N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABEO Health Care
- SOPH Health Care
- Exchange
- ABEO Nasdaq
- SOPH Nasdaq
- Market Cap
- ABEO 289.2M
- SOPH 231.8M
- IPO Year
- ABEO 1980
- SOPH 2021
- Fundamental
- Price
- ABEO $5.49
- SOPH $4.37
- Analyst Decision
- ABEO Strong Buy
- SOPH
- Analyst Count
- ABEO 6
- SOPH 0
- Target Price
- ABEO $18.17
- SOPH N/A
- AVG Volume (30 Days)
- ABEO 1.0M
- SOPH 116.1K
- Earning Date
- ABEO 11-13-2025
- SOPH 11-04-2025
- Dividend Yield
- ABEO N/A
- SOPH N/A
- EPS Growth
- ABEO N/A
- SOPH N/A
- EPS
- ABEO 0.99
- SOPH N/A
- Revenue
- ABEO $400,000.00
- SOPH $69,688,000.00
- Revenue This Year
- ABEO N/A
- SOPH $16.60
- Revenue Next Year
- ABEO $324.71
- SOPH $19.09
- P/E Ratio
- ABEO $5.69
- SOPH N/A
- Revenue Growth
- ABEO N/A
- SOPH 7.32
- 52 Week Low
- ABEO $3.93
- SOPH $2.58
- 52 Week High
- ABEO $7.54
- SOPH $4.92
- Technical
- Relative Strength Index (RSI)
- ABEO 45.42
- SOPH 57.32
- Support Level
- ABEO $5.21
- SOPH $3.93
- Resistance Level
- ABEO $5.73
- SOPH $4.71
- Average True Range (ATR)
- ABEO 0.24
- SOPH 0.38
- MACD
- ABEO 0.06
- SOPH -0.03
- Stochastic Oscillator
- ABEO 59.63
- SOPH 49.68
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.